Copy Link Print Information

Milatuzumab

(Synonyms: hLL1; MEDI-115)
7 Cited Publications
Avis client

Based on 7 publication(s) in Google Scholar

Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74 monoclonal antibody. CD74, a integral membrane protein, is associated with the promotion of B-cell growth and survival. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

  • Pureté : 99.39%
  • CAS No.: 899796-83-9
  • Masse moléculaire:145.66 kDa
  • Stockage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Milatuzumab
  • Experimental Validation Results for Milatuzumab
  • Experimental Validation Results for Milatuzumab
  • Experimental Validation Results for Milatuzumab
  • Experimental Validation Results for Milatuzumab
  • Experimental Validation Results for Milatuzumab
  • Experimental Validation Results for Milatuzumab
  • Experimental Validation Results for Milatuzumab
  • Milatuzumab Chemical Structure
    Milatuzumab Chemical Structure
CAS No.: 899796-83-9
Size
Prix
Stock
Quantité
Amount: USD 0.00
Please select quantity
or
or

* Veuillez sélectionner la quantité avant d'ajouter des articles.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Milatuzumab Product Recommendations:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Trouvez votre distributeur local Your local distributor: Hycultec GmbHHycultec
  • Activité biologique
  • Chemical Information
  • Protocole
  • Pureté et documentation
  • Références
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Milatuzumab

More
Customer Validation & Images
Cell Imaging/StainingWBFlow CytometryIF
  • Cell Imaging/Staining
  • WB
  • IF
  • Flow Cytometry
  • Flow Cytometry

Keywords

MOQ
Minimum order quantity
100 mg

Obtenir un devis En stock

Other size
Obtenir un devis
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Enregistrer
Sign in to MedChemExpress
Enregistrer un nouveau compte

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    Human IgG1 kappa

  • 1/16

    Immobilized hu-CD74-ECD-His can bind Milatuzumab. The EC50 for this effect is 3.941 ng/mL.

  • 1/16

    Flow Cytometry analysis of Raji cells labelling CD74 (red) with Milatuzumab (anti-CD74) (HY-P99731). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.

  • 1/16

    Milatuzumab purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Sep;12(35):e02838. [Abstract]

    Customer Validation
     HCAEC cells were treated with ox-LDL and anti-CD74 antibody (Milatuzumab: 15 mg/kg) for 12 hours, stained with 1 µg/ml WGA-Alexa 488 and CD80, and observed under a confocal microscope.

  • 1/16

    Milatuzumab purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Sep;12(35):e02838. [Abstract]

    Customer Validation
     Western blot analysis of migratory bodies and M1 macrophage-related markers in HCAEC cells treated with ox-LDL and anti-CD74 antibody (Milatuzumab: 15 mg/kg) was performed.

  • 1/16

    Milatuzumab purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Sep;12(35):e02838. [Abstract]

    Customer Validation
     Immunofluorescence images showing M1 macrophages and migrasomes in Control, AS, and AS_Anti CD74 (Milatuzumab: 15 mg/kg) groups. Red: WGA‐594 (labeling migrasomes); Green: iNOS (labeling M1 macrophages); Magenta: CD206 (labeling M2 macrophages); Blue: DAPI (nuclei).

  • 1/16

    Milatuzumab purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Aug 6;12(8):e009024. [Abstract]

    Customer Validation
     Macrophages derived from THP-1 cells treated with anti-CD74 (Milatuzumab) were co-cultured. Phagocytic efficiency was quantified as the percentage of dual-fluorescence-positive macrophages (upper right quadrant).

  • 1/16

    Milatuzumab purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Aug 6;12(8):e009024. [Abstract]

    Customer Validation
     Flow cytometry was used to detect differences in phagocytic function among the control group, cisplatin group, and combination therapy group with anti-CD74 Ab (5 µg/mL). THP-1-derived macrophages were co-cultured with SiHa cells.

  • Milatuzumab Chemical Structure
    1/16
  • Milatuzumab
  • Immobilized hu-CD74-ECD-His can bind Milatuzumab. The EC50 for this effect is 3.941 ng/mL.
  • Flow Cytometry analysis of Raji cells labelling CD74 (red) with Milatuzumab (anti-CD74) (HY-P99731). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.